Literature DB >> 29980611

Temporal Requirement for Pulmonary Resident and Circulating T Cells during Virulent Francisella tularensis Infection.

Lydia M Roberts1, Tara D Wehrly1, Robin M Ireland1, Deborah D Crane1, Dana P Scott2, Catharine M Bosio3.   

Abstract

The lung is a complex organ with anatomically distinct pools of T cells that play specific roles in combating infection. Our knowledge regarding the generation and/or maintenance of immunity by parenchymal or circulating T cells has been gathered from either persistent (>60 d) or rapidly cleared (<10 d) infections. However, the roles of these distinct T cell pools in infections that are cleared over the course of several weeks are not understood. Clearance of the highly virulent intracellular bacterium Francisella tularensis subspecies tularensis (Ftt) following pulmonary infection of immune animals is a protracted T cell-dependent process requiring ∼30-40 d and serves as a model for infections that are not acutely controlled. Using this model, we found that intranasal vaccination increased the number of tissue-resident CD4+ effector T cells, and subsequent challenge of immune mice with Ftt led to a significant expansion of polyfunctional parenchymal CD4+ effector T cells compared with the circulating pool. Despite the dominant in vivo response by parenchymal CD4+ T cells after vaccination and challenge, circulating CD4+ T cells were superior at controlling intracellular Ftt replication in vitro. Further examination in vivo revealed temporal requirements for resident and circulating T cells during Ftt infection. These requirements were in direct contrast to other pulmonary infections that are cleared rapidly in immune animals. The data in this study provide important insights into the role of specific T cell populations that will be essential for the design of novel effective vaccines against tularemia and potentially other agents of pulmonary infection.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29980611      PMCID: PMC6086594          DOI: 10.4049/jimmunol.1800052

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection against pulmonary virus infection.

Authors:  Tao Wu; Yinghong Hu; Young-Tae Lee; Keith R Bouchard; Alexandre Benechet; Kamal Khanna; Linda S Cauley
Journal:  J Leukoc Biol       Date:  2013-09-04       Impact factor: 4.962

2.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Authors:  Rebecca V Anderson; Deborah D Crane; Catharine M Bosio
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

3.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

4.  Cutting edge: contribution of lung-resident T cell proliferation to the overall magnitude of the antigen-specific CD8 T cell response in the lungs following murine influenza virus infection.

Authors:  Jodi McGill; Kevin L Legge
Journal:  J Immunol       Date:  2009-10-01       Impact factor: 5.422

5.  Inclusion of Epitopes That Expand High-Avidity CD4+ T Cells Transforms Subprotective Vaccines to Efficacious Immunogens against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Deborah D Crane; Tara D Wehrly; Joshua R Fletcher; Bradley D Jones; Catharine M Bosio
Journal:  J Immunol       Date:  2016-08-19       Impact factor: 5.422

6.  Cutting edge: control of Mycobacterium tuberculosis infection by a subset of lung parenchyma-homing CD4 T cells.

Authors:  Shunsuke Sakai; Keith D Kauffman; Jason M Schenkel; Cortez C McBerry; Katrin D Mayer-Barber; David Masopust; Daniel L Barber
Journal:  J Immunol       Date:  2014-03-03       Impact factor: 5.422

7.  CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection.

Authors:  Brian J Laidlaw; Nianzhi Zhang; Heather D Marshall; Mathew M Staron; Tianxia Guan; Yinghong Hu; Linda S Cauley; Joe Craft; Susan M Kaech
Journal:  Immunity       Date:  2014-10-09       Impact factor: 31.745

8.  Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia.

Authors:  Deborah D Crane; Dana P Scott; Catharine M Bosio
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

9.  CD4 T Cell-Derived IFN-γ Plays a Minimal Role in Control of Pulmonary Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1 to Prevent Lethal Disease.

Authors:  Shunsuke Sakai; Keith D Kauffman; Michelle A Sallin; Arlene H Sharpe; Howard A Young; Vitaly V Ganusov; Daniel L Barber
Journal:  PLoS Pathog       Date:  2016-05-31       Impact factor: 6.823

10.  Skin-resident memory CD4+ T cells enhance protection against Leishmania major infection.

Authors:  Nelson D Glennie; Venkata A Yeramilli; Daniel P Beiting; Susan W Volk; Casey T Weaver; Phillip Scott
Journal:  J Exp Med       Date:  2015-07-27       Impact factor: 14.307

View more
  3 in total

1.  Circulating T Cells Are Not Sufficient for Protective Immunity against Virulent Francisella tularensis.

Authors:  Lydia M Roberts; Tara D Wehrly; Ian Leighton; Patrick Hanley; Jamie Lovaglio; Brian J Smith; Catharine M Bosio
Journal:  J Immunol       Date:  2022-02-11       Impact factor: 5.422

2.  Cutting Edge: Lung-Resident T Cells Elicited by SARS-CoV-2 Do Not Mediate Protection against Secondary Infection.

Authors:  Lydia M Roberts; Forrest Jessop; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2021-10-04       Impact factor: 5.422

Review 3.  Host Immunity and Francisella tularensis: A Review of Tularemia in Immunocompromised Patients.

Authors:  Olivier Bahuaud; Cécile Le Brun; Adrien Lemaignen
Journal:  Microorganisms       Date:  2021-12-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.